Hsbc Holdings PLC Has $3.32 Million Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Hsbc Holdings PLC increased its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 221.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 42,682 shares of the company's stock after buying an additional 29,398 shares during the period. Hsbc Holdings PLC owned 0.09% of Prestige Consumer Healthcare worth $3,324,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in Prestige Consumer Healthcare by 3.2% during the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company's stock worth $19,630,000 after acquiring an additional 8,533 shares during the last quarter. Avior Wealth Management LLC lifted its holdings in Prestige Consumer Healthcare by 1,570.7% during the 4th quarter. Avior Wealth Management LLC now owns 8,554 shares of the company's stock worth $668,000 after purchasing an additional 8,042 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Prestige Consumer Healthcare by 5.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company's stock worth $49,667,000 after purchasing an additional 33,844 shares during the last quarter. Norges Bank bought a new stake in Prestige Consumer Healthcare in the 4th quarter valued at $40,009,000. Finally, Barclays PLC grew its holdings in Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company's stock valued at $6,665,000 after buying an additional 71,730 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Analyst Upgrades and Downgrades

PBH has been the subject of a number of recent research reports. Canaccord Genuity Group boosted their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, February 7th. DA Davidson increased their target price on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Oppenheimer lifted their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. Royal Bank of Canada increased their price target on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a "sector perform" rating in a research report on Friday, March 21st. Finally, StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $93.33.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Price Performance

PBH traded up $2.00 during trading on Friday, hitting $84.23. 340,824 shares of the stock traded hands, compared to its average volume of 290,707. The business has a 50 day moving average price of $83.34 and a 200 day moving average price of $80.82. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. Prestige Consumer Healthcare Inc. has a twelve month low of $62.35 and a twelve month high of $90.04. The company has a market cap of $4.17 billion, a price-to-earnings ratio of 19.73, a PEG ratio of 2.69 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.